Revenue from operations of the company for Q4FY21 grew by 17.01% YoY from Rs. 921.31 Cr in Q4FY20 to Rs. 1078.01 Cr in Q4FY21.
EBITDA in Q4FY21 stood at Rs. 258 Cr & in Q4FY20 at Rs. 215.42 Cr, thus showing growth of 19.77%.
Company saw a good growth in PBT in Q4FY21 of 22.35%, rising from Rs. 184.64 Cr in Q4FY20 to Rs. 225.9 Cr in Q4FY21.
PAT rose from Rs. 142.24 Cr in Q4FY20 to Rs. 169.18 Cr in Q4FY21, thus showing an increase of 18.94%.
Consolidated:
Revenue from operations for Q4FY21 stood at Rs. 1115.93 Cr & for Q4FY20 stood at Rs. 965.47, revealing a good increase in revenue by 15.58% YoY.
EBITDA witnessed a growth of 22.51% from Rs. 224.53 in Q4FY20 to Rs. 275.07 Cr in Q4FY21.
PBT grew by 25.32% from Rs. 188.42 Cr in Q4FY20 to Rs. 236.12 Cr in Q4FY21.
Even PAT grew by 24.01% YoY from Rs. 142.47 Cr in Q4FY20 to Rs. 176.67 Cr in Q4FY21.
Segment Performance:
Company has 3 operating segments namely, Life Science Chemicals, Performance & other chemicals & Others.
Revenue of Life Science Chemicals grew by 22.57% from Rs. 254.45 Cr in Q4FY20 to Rs. 311.89 Cr in Q4FY21.
Revenue of Performance & other Chemicals grew by 9.74% from Rs. 744.62 Cr in Q4FY20 to Rs. 817.16 Cr in Q4FY21.
Revenue of Others (Others being a small portion of all the segments together) grew by around 63% from Rs. 9.16 Cr in Q4FY20 to Rs. 14.93 Cr in Q4FY21.
Total revenue for Q4FY21, however, increased by 15.58% from Rs. 965.47 Cr in Q4FY20.
Segment results (with all the segments taken together) for Q4FY21 stood at Rs. 238.37 Cr, rising by 30.64% from Rs. 182.46 Cr in Q4FY20.
PBT from the same stood at Rs. 236.12 Cr in Q4FY21 & for Q4FY20 stood at Rs. 188.42, thus showing a growth of 25.32%.
FY21 financial results:
Standalone:
Company’s Revenue from operations for the FY20 stood at Rs. 3905.66 and then falling by 10.07% stood at Rs. 3512.35 for FY21.
A rise of 3.04% in EBITDA can be seen i.e., rising from Rs. 921.95 Cr in FY20 to Rs. 949.95 Cr in FY21.
PBT revealed growth of 3.14% YoY standing at Rs. 827.75 Cr for FY21 from Rs. 802.54 Cr in FY20.
On the other hand, PAT revealed a small fall of 1.45% YoY, falling from Rs. 640.17 Cr in FY20 to Rs. 630.89 Cr in FY21.
Consolidated:
Consolidated Revenue from operations showed a downfall of 8.83% from Rs. 4093.06 in FY20 to Rs. 3731.47 Cr.
The reason for downfall in revenue was the lockdown restrictions due to pandemic. However, operations were started slowly ina phased manner as restrictions eased up.
EBITDA revealed the growth of 4.3% from Rs. 985.03 Cr in FY20 to Rs. 1027.35 Cr in FY21.
PBT from Rs. 845.42 Cr in FY20 rose by 4.29% and stood at Rs. 881.68 Cr in FY21.
However, PAT witnessed a small decline of 1.62% from Rs. 670.91 Cr in FY20 to Rs. 660.02 Cr in FY21.
Segment Performance:
Revenue of Life Science Chemicals fell by 2.84% from Rs. 1251.95 Cr in Q4FY20 to Rs. 1216.37 Cr in Q4FY21.
Revenue of Performance & other Chemicals fell by 12.15% from Rs. 2984.5 Cr in Q4FY20 to Rs. 2621.88 Cr in Q4FY21.
Revenue of Others (Others being a small portion of all the segments together) grew by around 31.63% from Rs. 36.83 Cr in Q4FY20 to Rs. 48.48 Cr in Q4FY21.
Total revenue from all the segments for FY20 stood at Rs. 4093.06 which fell by 8.83% to stand at Rs. 3731.47 Cr in FY21.
Segment results (with all the segments taken together) for Q4FY21 stood at Rs. 825.03 Cr, falling by 1.58% YoY from Rs. 838.26 Cr in Q4FY20.
However, PBT from the same stood at Rs. 881.68 Cr in Q4FY21 & for Q4FY20 stood at Rs. 845.42, thus showing a growth of 4.29%.
Dividend:
The Board of Directors of the company have recommended a dividend of Rs. 20/share.
Download
